Absent FDA Guidance on Sequencing-Based Tests, Personalized Rx Experts Weigh in with Ideas
October 13, 2010
Absent FDA Guidance on Sequencing-Based Tests, Personalized Rx Experts Weigh in with Ideas
As personalized medicine stakeholders in industry and academia set their sights on sequencing-based platforms, the absence of regulation poses challenges but inspires creative suggestions.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA's SEQC Expands to Six Studies; RNA-seq Technical Reproducibility Work to Begin by Year End
November 29, 2011 / In Sequence - Sequenom Considering Illumina, SOLiD for Down Syndrome Test; Plans to Launch LDT by End of 2011
May 18, 2010 / In Sequence - GenomeWeb Feature: Will the Future of Genomics be Consumer Driven?
March 4, 2013 / GenomeWeb Daily News - Researchers Rank MiSeq over PGM for Usability; Expect Their Sequencing Output to Grow by Half in 2013
January 22, 2013 / In Sequence - Illumina Growing Clinical and Dx Business with Submission of MiSeqDx, Two CF Assays to FDA
January 9, 2013 / Clinical Sequencing News